Literature DB >> 7755352

Outcome after spinal reirradiation for malignant epidural spinal cord compression.

D Schiff1, E G Shaw, T L Cascino.   

Abstract

Radiotherapy is effective for most cases of spinal cord compression. Although recurrent spinal cord compression is a common problem, little is known about whether reirradiation preserves neurologic function and what risk of radiation myelopathy it carries. To investigate this question, we reviewed patients at the Mayo Clinic between 1975 and 1992 undergoing two or more courses of radiotherapy to the same segment of the spinal column with radiographically documented epidural disease at the time of reirradiation to determine outcome as measured by the ability to walk and by survival. Fifty-four patients met the study criteria. Radiation doses for the first course ranged from 2,250 to 5,400 cGy (median, 3,000 cGy), and total dose for all courses to the reirradiated spinal segment ranged from 3,650 to 8,089 cGy (median, 5,425 cGy). All patients were ambulatory following the first course of radiation, 40 (74%) were ambulatory at the onset of reirradiation, and 42 (78%) were ambulatory at the end of reirradiation. Thirty-seven patients (69%) remained ambulatory at their last follow-up 6 days to 80 months following reirradiation (median, 4.7 months). Five patients eventually became nonambulatory 6.5 to 35 months following reirradiation. Median survival for all patients following reirradiation was 4.2 months. We conclude that for cancer patients with progressive epidural disease following radiotherapy, reirradiation frequently preserves ambulation and carries minimal risk of radiation myelopathy during the patients' lifetime.

Entities:  

Mesh:

Year:  1995        PMID: 7755352     DOI: 10.1002/ana.410370507

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Intramedullary spinal cord metastasis from colonic carcinoma presenting as Brown-Séquard syndrome: a case report.

Authors:  Mohammed A Kaballo; Darren D Brennan; Mazen El Bassiouni; Stephen J Skehan; Rajnish K Gupta
Journal:  J Med Case Rep       Date:  2011-08-02

Review 2.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

3.  Recurrent spinal epidural metastases: a prospective study with a complete follow up.

Authors:  J J van der Sande; W Boogerd; R Kröger; A C Kappelle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

4.  In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis.

Authors:  Charles E Rutter; James B Yu; David J Carlson; Zain A Husain; Sherry Zhao; James Picone; Ranjit S Bindra
Journal:  J Radiosurg SBRT       Date:  2014

Review 5.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

6.  Reducing the overall treatment time for radiotherapy of metastatic spinal cord compression (MSCC): 3-year results of a prospective observational multi-center study.

Authors:  Dirk Rades; Fabian Fehlauer; Axel Hartmann; Ingeborg Wildfang; Johann H Karstens; Winfried Alberti
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

Review 7.  Radiotherapeutic approaches to metastatic disease.

Authors:  Edward Chow; Jackson Wu; Andrew Loblaw; Carlos A Perez
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

8.  Epidural Spinal Cord Compression.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Treat Options Neurol       Date:  2004-07       Impact factor: 3.598

9.  Overall survival after reirradiation of spinal metastases - independent validation of predictive models.

Authors:  Daniel Buergy; Lena Siedlitzki; Judit Boda-Heggemann; Frederik Wenz; Frank Lohr
Journal:  Radiat Oncol       Date:  2016-03-08       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.